The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.

被引：0
|
作者：
Mitsiades, N
Mitsiades, CS
Poulaki, V
Fanourakis, G
Chauhan, D
Munshi, NC
Hideshima, T
Anderson, KC
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3220
引用
收藏
页码：815A / 815A
页数：1
相关论文
共 50 条
  • [41] The synergy effects of proteasome inhibitor PS-341 and TRAIL on the apoptosis of human tumor cells
    Toh, U
    Sayers, TJ
    Seki, N
    Shirouzu, K
    Yamana, H
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 154 - 154
  • [42] Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Zou, W
    Yue, P
    Lin, N
    He, M
    Zhou, ZM
    Lonial, S
    Khuri, FR
    Wang, BH
    Sun, SY
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 273 - 280
  • [43] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Orlowski, RZ
    Stinchcombe, TE
    Mitchell, BS
    Shea, TC
    Baldwin, AS
    Stahl, S
    Adams, J
    Esseltine, DL
    Elliott, PJ
    Pien, CS
    Guerciolini, R
    Anderson, JK
    Depcik-Smith, ND
    Bhagat, R
    Lehman, MJ
    Novick, SC
    O'Connor, OA
    Soignet, SL
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
  • [44] A phase II multicenter study of the proteasome inhibitor bortezomib (VELCADE™, formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease.
    Richardson, P
    Barlogie, B
    Berenson, J
    Traynor, A
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, V
    Srkalovic, G
    Alsina, M
    Alexanian, R
    Siegel, D
    Orlowski, RZ
    Kuter, D
    Limentani, SA
    Lee, S
    Esseltine, DL
    Kauffman, M
    Adams, J
    Schenkein, DP
    Anderson, KC
    BLOOD, 2002, 100 (11) : 104A - 104A
  • [45] Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.
    Hideshima, T
    Mitsiades, C
    Akiyama, M
    Hayashi, T
    Chauhan, D
    Richardson, PG
    Schlossman, RL
    Podar, K
    Munshi, NC
    Mitsiades, N
    Anderson, KC
    BLOOD, 2002, 100 (11) : 814A - 814A
  • [46] Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Lara, PN
    Davies, AM
    Mack, PC
    Mortenson, MM
    Bold, RJ
    Gumerlock, PH
    Gandara, DR
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 40 - 46
  • [47] Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas.
    O'Connor, OA
    Moskowitz, CH
    Wright, JJ
    MacGregor-Cortelli, B
    Straus, D
    Furst, D
    Horse-Grant, D
    Schenkein, DP
    Zelenetz, AD
    BLOOD, 2002, 100 (11) : 774A - 774A
  • [48] The proteasome inhibitor PS-341 inhibits the growth of metastatic human prostate cancer in bone.
    Whang, PG
    Iglesias, RC
    Gates, JJ
    Lieberman, JR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S411 - S411
  • [49] Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts
    Nawrocki, ST
    Bruns, CJ
    Harbison, MT
    Bold, RJ
    Gotsch, BS
    Abbruzzese, JL
    Elliott, P
    Adams, J
    McConkey, DJ
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (14) : 1243 - 1253
  • [50] Proteasome inhibition by PS-341: A phase I study.
    Hamilton, A
    Eder, JP
    Pavlick, A
    Clark, JW
    Chachoua, A
    Ryan, DP
    Farrell, K
    Wasserstrom, H
    Liebes, L
    Wright, J
    Elliott, P
    Adams, J
    Muggia, F
    CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
12345